$\Box$ 

# FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							

Estimated average burden	
hours per response:	0.5

1. Name and Address of Reporting Person <sup>*</sup> Baker Brothers Life Sciences Capital (GP), LLC			2. Issuer Name and Ticker or Trading Symbol <u>INCYTE CORP</u> [ INCY ]		ationship of Reporting P ( all applicable) Director Officer (give title	erson(s) to Issuer 10% Owner Other (specify
(Last) 667 MADISON	(First) AVENUE, 17	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 11/09/2007		below)	below)
(Street) NEW YORK (City)	NY (State)	US 10021 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	vidual or Joint/Group Fil Form filed by One Re Form filed by More th Person	eporting Person

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

Table 1 - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned										
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code ( 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(instr. 4)
Common Stock <sup>(1)(2)</sup>	11/09/2007		Р		3,629	A	\$7.8958	1,733,617	I	Through Partnership <sup>(3)</sup>
Common Stock <sup>(1)(2)</sup>	11/09/2007		Р		198,883	A	\$7.7027	1,932,500	I	Through Partnership <sup>(3)</sup>
Common Stock <sup>(1)(2)</sup>	11/12/2007		Р		140,951	A	\$8.3001	2,073,451	I	Through Partnership <sup>(3)</sup>
Common Stock <sup>(1)(2)</sup>	11/12/2007		Р		172,694	A	\$8.2005	2,246,145	Ι	Through Partnership <sup>(3)</sup>
Common Stock <sup>(1)(2)</sup>	11/12/2007		Р		21,397	A	\$8.2338	2,267,542	Ι	Through Partnership <sup>(3)</sup>
Common Stock <sup>(1)(2)</sup>	11/12/2007		Р		11,165	A	\$7.9953	2,278,707	I	Through Partnership <sup>(3)</sup>
Common Stock <sup>(1)(2)</sup>	11/13/2007		Р		23,377	A	\$8.299	2,302,084	Ι	Through Partnership <sup>(3)</sup>
Common Stock <sup>(1)(2)</sup>	11/13/2007		Р		14,490	A	\$8.2234	2,316,574	I	Through Partnership <sup>(3)</sup>
Common Stock <sup>(1)(2)</sup>	11/13/2007		Р		19,844	A	\$8.2585	2,336,418	I	Through Partnership <sup>(3)</sup>
Common Stock <sup>(1)(2)</sup>	11/13/2007		Р		87,343	A	\$8.2505	2,423,761	I	Through Partnership <sup>(3)</sup>

 

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		Expiration Date		Expiration Date		Expiration Date (Month/Day/Year) ed		e Amount of		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares										
1. Name an	d Address of	Reporting Person <sup>*</sup>																			

Baker Brothers Life Sciences Capital (GP), LLC

(Last) (First) (Middle)

667 MADISON AVENUE, 17TH FLOOR

NEW YORK	NY	US 10021
(City)	(State)	(Zip)
1. Name and Address of BAKER JULIA		
(Last) 667 MADISON AV	(First) ZENUE, 17TH FLOC	(Middle) DR
(Street) NEW YORK	NY	US 10021
(City)	(State)	(Zip)

#### Explanation of Responses:

1. In addition to Baker Brothers Life Sciences Capital (GP), LLC, this Form 4 is being filed by Julian C. Baker who has the same business address as Baker Brothers Life Sciences Capital (GP), LLC and may be deemed to have a pecuniary interest in securities owned by it. Julian C. Baker is a Director of the Issuer. Because of certain relationships with other security holders of the Issuer, the Reporting Persons are filing solely for informational purposes as if they were a member of a group of such shareholders. (Continued in footnote 2).

2. However, the Reporting Persons disclaim that they and any other person or persons, in fact constitute a "group" for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, or Rule 13d-5 thereunder or that they are the beneficial owners of securities owned by any such other persons, and each of them disclaims beneficial ownership of securities reported herein except to the extent of their pecuniary interest, if any, therein.

3. Represents securities owned directly by Baker Brothers Life Sciences, L.P., the sole general partner of which is Baker Brothers Life Sciences Capital, L.P., a limited partnership the sole general partner of which is Baker Brothers Life Sciences Capital (GP), LLC. Julian C. Baker is a controlling member of Baker Brothers Life Sciences Capital (GP), LLC.

<u>/s/ Julian C. Baker, as</u>	
<u>Managing Member of Baker</u>	11/12/2007
Brother Life Sciences Capital	<u>11/13/2007</u>
<u>(GP), LLC</u>	
/s/ Julian C. Baker	11/13/2007

\*\* Signature of Reporting Person

<u>11/13/2007</u> Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.